RTU 1096

Drug Profile

RTU 1096

Alternative Names: RTU-1096; VAP-1 inhibitors - Mallinckrodt

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator R-Tech Ueno
  • Developer Hokkaido University; Kyushu University; Sucampo Pharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis; Cataracts; Contact dermatitis; Diabetic macular oedema; Diabetic neuropathies; Diabetic retinopathy; Psoriasis

Most Recent Events

  • 13 Feb 2018 Sucampo Pharmaceuticals has been acquired by Mallinckrodt
  • 09 Nov 2016 Discontinued - Phase-I for Atopic dermatitis (In volunteers) in Japan (PO) before November 2016
  • 09 Nov 2016 Discontinued - Phase-I for Diabetic macular oedema in Japan (PO) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top